A Key Trend Influencing the Genitourinary Drugs Market Is the Approval of a First-in-Class Oral Therapy for UTI Treatment in Adolescents and Adults

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Genitourinary Drugs Market Expected To Change Between 2026 And 2030?

The genitourinary drugs market size has experienced consistent expansion in recent years. It is anticipated to grow from $31.02 billion in 2025 to $31.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 3.1%. The historical increase in this market can be attributed to several factors including the prevalence of urinary tract infections, the aging population, the incidence of hormonal disorders, the expansion of hospital pharmacies, and the widespread adoption of prescription drugs.

The genitourinary drugs market is anticipated to experience consistent expansion over the coming years. Its valuation is projected to reach $35.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 2.8%. This expansion during the forecast period can be primarily linked to advancements like personalized urology treatments, the rise of digital health platforms, increased reproductive health awareness, the adoption of minimally invasive therapies, and the proliferation of specialty clinics. Key developments expected within this period include a heightened demand for treatments for UTI and BPH, the increasing application of hormonal and fertility therapies, the broader availability of oral and topical drug formulations, an enhanced focus on both women’s and men’s urological health, and the expansion of online pharmacy distribution channels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24548&type=smp

Which Economic Or Industry Drivers Are Impacting The Genitourinary Drugs Market?

The increasing occurrence of genitourinary disorders is projected to fuel the expansion of the genitourinary drugs market in the future. These disorders are medical conditions impacting the genitourinary system, which encompasses both the urinary and reproductive organs, covering issues like infections, cancers, and functional or structural problems. The rising prevalence of genitourinary disorders is linked to the aging population, as age-related alterations heighten the risk of urinary and reproductive health issues. Genitourinary drugs are crucial for addressing these conditions by targeting urinary and reproductive system ailments, providing alleviation from infections, inflammation, and dysfunction. They enhance patient outcomes through effective, convenient, and specific treatments, thereby improving overall quality of life. For example, in April 2024, a report from the American Cancer Society, a US-based non-profit organization, indicated that around 20 million new cancer cases were diagnosed globally in 2022, resulting in 9.7 million deaths, with cancer cases expected to climb to 35 million by 2050. Consequently, the expanding prevalence of genitourinary disorders is driving the growth of the genitourinary drugs market.

How Is The Genitourinary Drugs Market Structured Across Different Segments?

The genitourinary drugs market covered in this report is segmented –

1) By Product: Urologicals, Hormonal Therapy, Gynecological, Anti-Infectives, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Application: Urinary Tract Infections (UTIs), Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Overactive Bladder, Bladder Cancer, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Urologicals: Benign Prostatic Hyperplasia (BPH) Drugs, Urinary Incontinence Drugs, Overactive Bladder (OAB) Drugs, Urolithiasis (Kidney Stone) Drugs, Erectile Dysfunction Drugs

2) By Hormonal Therapy: Estrogen Therapy, Progestin Therapy, Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists, Androgen Replacement Therapy, Selective Estrogen Receptor Modulators (SERMs)

3) By Gynecological: Contraceptives, Menopausal Hormone Therapy, Fertility Drugs, Drugs for Endometriosis, Drugs for Polycystic Ovary Syndrome (PCOS)

4) By Anti-Infectives: Urinary Tract Infection (UTI) Drugs, Sexually Transmitted Infection (STI) Drugs, Vaginal Antifungals, Antivirals

5) By Other Products: Drugs for Chronic Pelvic Pain, Bladder Cancer Therapies, Interstitial Cystitis Drugs, Pelvic Organ Prolapse Treatment Drugs, Adjunctive Therapies

Which Trends Are Shaping The Future Of The Genitourinary Drugs Market?

Major companies within the genitourinary drugs market are concentrating on developing innovative products, such as oral antibiotics, to enhance treatment convenience, improve patient adherence, and effectively combat infections. Oral antibiotics are antibacterial medications taken by mouth to address infections caused by bacteria. For instance, in March 2025, GSK plc, a UK-based pharmaceutical company, secured approval from the US Food and Drug Administration (FDA) for Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections in women and girls aged 12 and older, where these infections are caused by susceptible bacteria. This drug is a novel, first-in-class oral antibiotic that operates by inhibiting bacterial DNA replication, specifically targeting two critical enzymes: DNA gyrase and topoisomerase IV. Unlike traditional antibiotics, it binds to unique sites to overcome resistance, offering a targeted mechanism with enhanced safety and efficacy.

Which Major Players Dominate The Genitourinary Drugs Market?

Major companies operating in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Société Anonyme, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., Asieris Pharmaceuticals, Sun Pharmaceutical Industries Ltd.

Read the full genitourinary drugs market report here:

https://www.thebusinessresearchcompany.com/report/genitourinary-drugs-global-market-report

What Are The Top-Performing Regions Within The Genitourinary Drugs Market?

North America was the largest region in the genitourinary drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genitourinary drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Genitourinary Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24548&type=smp

Browse Through More Reports Similar to the Global Genitourinary Drugs Market 2026, By The Business Research Company

Genito Urinary Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Generic Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

Pharmaceutical Label Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795